Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF


Clinical Trial Description

The current study was aimed at assessing whether a treatment based on combination of rifaximin and simvastatin would be effective in patients with decompensated cirrhosis to prevent ACLF development Considering that statins have been scarcely investigated in patients with decompensated cirrhosis due to a concern of potential higher liver and muscle toxicity in this population, a first LIVERHOPE_SAFETY clinical trial (unpublished) was undergone to assess safety and toxicity of statins with decompensated cirrhosis. As a preliminary result of the LIVERHOPE_SAFETY clinical trial, it was concluded that the dose of Simvastatin 20mg per day plus Rifaximin is not associated to a higher risk of liver or muscle toxicity in patients with decompensated cirrhosis and simvastatin 20 mg was established for the LIVERHOPE_EFFICACY study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03780673
Study type Interventional
Source Institut d'Investigacions Biomèdiques August Pi i Sunyer
Contact
Status Completed
Phase Phase 2/Phase 3
Start date January 3, 2019
Completion date December 1, 2022

See also
  Status Clinical Trial Phase
Terminated NCT03219372 - Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence Phase 2
Recruiting NCT03624517 - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices Phase 4
Recruiting NCT04057287 - Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)
Recruiting NCT04089878 - "To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt N/A
Completed NCT04212286 - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC N/A
Completed NCT04474743 - Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
Recruiting NCT03694691 - Developing Viability Index for Machine Perfused Livers N/A
Terminated NCT04072601 - Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis Phase 4
Terminated NCT03878563 - Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)
Terminated NCT04160039 - Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit N/A
Recruiting NCT04191369 - EGD vs EUS in Diagnosing Portal Hypertension in Cirrhotic Patients. N/A
Completed NCT03083925 - Viatorr CX Case-control Study for Complications of Portal Hypertension
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Recruiting NCT02484573 - Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol) N/A
Recruiting NCT04357600 - Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B Phase 1/Phase 2
Completed NCT03156426 - Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis
Active, not recruiting NCT03868397 - Preoperative Portal and Splanchnic Flow Measurement Using MRI N/A
Terminated NCT03650660 - Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
Completed NCT03871894 - Indirect Calorimeter Based Study in Patients With Liver Cirrhosis N/A
Completed NCT03283176 - Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin